Table 2 Overall disposition of the 6139 randomized patients in the sitagliptin and non-exposed groups
From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
| Sitagliptin 100 mg | Non-Exposed | |
|---|---|---|
| RANDOMIZED, N | 3415 | 2724 |
| n (%) | n (%) | |
| DISCONTINUED* | 1191 (34.9) | 1076 (39.5) |
| Reason for discontinuation | ||
| Clinical adverse experience | 119 (3.5) | 113 (4.1) |
| Laboratory adverse experience | 38 (1.1) | 22 (0.8) |
| Lack of efficacy† | 458 (13.4) | 381 (14.0) |
| Patient discontinued for other | 152 (4.5) | 176 (6.5) |
| Patient moved | 33 (1.0) | 19 (0.7) |
| Patient withdrew consent | 186 (5.4) | 203 (7.4) |
| Protocol specified discontinuation criteria | 48 (1.4) | 44 (1.6) |
| Protocol deviation | 58 (1.7) | 50 (1.8) |
| Lost to follow-up | 97 (2.8) | 65 (2.4) |
| Site terminated | 2 (0.1) | 3 (0.1) |